Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Future directions for the treatment of WAHA

Catherine Broome • 13 Oct 2021
LLM 2021
Anemias

Catherine Broome, MD, Lombardi Cancer Center, Washington, DC, discusses the developments in the treatment landscape for warm autoimmune hemolytic anemia (WAHA). Current investigations into Bruton’s tyrosine kinase (BTK) inhibitors and spleen tyrosine kinase (SYK) inhibitors will hopefully improve the current armamentarium of treatments for WAHA. Dr Broome additionally comments on neonatal Fc receptor (FcRn)-agonists, which have shown promise in preliminary trials. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Sanofi, Argenx, Rigel, Alexion, Annexon, Cellphire

More from Catherine Broome

1:50
Unmet needs in the treatment and management of cold agglutinin disease
Catherine Broome • 18 Dec 2023
1:30
Targeting the complement cascade in autoimmune hemolytic anemias
Catherine Broome • 18 Dec 2023
1:59
Sutimlimab in cold agglutinin disease: a post-hoc analysis of safety data from CARDINAL & CADENZA
Catherine Broome • 18 Dec 2023
2:50
Time to achieve platelet count response with efgartigimod in patients with persistent/chronic ITP
Catherine Broome • 18 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
2:13
SATISFY: mitapivat in patients with erythrocyte membranopathies
Kevin Kuo • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals